China SXT Pharmaceuticals Inc
SXTC1.660USD
+0.240+16.90%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
22.85MMarket Cap
--P/E TTM
More Details of China SXT Pharmaceuticals Inc Company
China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
China SXT Pharmaceuticals Inc Info
Ticker SymbolSXTC
Company nameChina SXT Pharmaceuticals Inc
IPO dateJan 04, 2019
CEOMr. Lim Sze (Simon) Beng
Number of employees75
Security typeOrdinary Share
Fiscal year-endJan 04
Address178 Taidong Road North
CityTAIZHOU
Stock exchangeNASDAQ Capital Market Consolidated
CountryChina
Postal code225300
Phone8652386298290
Websitehttps://www.sxtchina.com/
Ticker SymbolSXTC
IPO dateJan 04, 2019
CEOMr. Lim Sze (Simon) Beng
Company Executives of China SXT Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Feng Zhou
Mr. Feng Zhou
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
532.00
-94.18%
Mr. Lim Sze (Simon) Beng
Mr. Lim Sze (Simon) Beng
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Xiaodong Pan
Mr. Xiaodong Pan
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jun Zheng
Mr. Jun Zheng
Director
Director
--
--
Mr. Xiaodong Ji
Mr. Xiaodong Ji
Independent Director
Independent Director
--
--
Mr. Tong Liu
Mr. Tong Liu
Independent Director
Independent Director
--
--
Mr. Lip Chee Yong
Mr. Lip Chee Yong
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Feng Zhou
Mr. Feng Zhou
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
532.00
-94.18%
Mr. Lim Sze (Simon) Beng
Mr. Lim Sze (Simon) Beng
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Xiaodong Pan
Mr. Xiaodong Pan
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jun Zheng
Mr. Jun Zheng
Director
Director
--
--
Mr. Xiaodong Ji
Mr. Xiaodong Ji
Independent Director
Independent Director
--
--
Mr. Tong Liu
Mr. Tong Liu
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Regular TCMP
1.44M
82.86%
Advanced TCMP
258.42K
14.84%
Others
40.02K
2.30%
By RegionUSD
Name
Revenue
Proportion
People's Republic of China
1.74M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Regular TCMP
1.44M
82.86%
Advanced TCMP
258.42K
14.84%
Others
40.02K
2.30%
Shareholding Stats
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foong Soon Hong (Randy)
9.13%
Seng (Tan Soo)
8.96%
Tan (Cheng Guan)
8.79%
Ching (Choon Hwa)
8.45%
Invesco Capital Management LLC
0.08%
Other
64.60%
Shareholders
Shareholders
Proportion
Foong Soon Hong (Randy)
9.13%
Seng (Tan Soo)
8.96%
Tan (Cheng Guan)
8.79%
Ching (Choon Hwa)
8.45%
Invesco Capital Management LLC
0.08%
Other
64.60%
Shareholder Types
Shareholders
Proportion
Individual Investor
35.32%
Investment Advisor
0.13%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.01%
Other
64.49%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
220.10K
0.19%
+206.04K
2025Q2
20
28.22K
2.38%
-47.81K
2025Q1
20
28.22K
0.02%
-47.80K
2024Q4
22
74.93K
15.02%
+42.94K
2024Q3
24
33.98K
13.64%
+10.51K
2024Q2
21
35.50K
15.27%
+22.93K
2024Q1
24
15.92K
23.88%
+2.99K
2023Q4
23
15.02K
23.00%
+2.57K
2023Q3
23
16.29K
24.79%
+5.61K
2023Q2
20
14.62K
58.36%
+11.76K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foong Soon Hong (Randy)
10.59M
9.13%
+10.59M
--
Jul 29, 2025
Seng (Tan Soo)
10.39M
8.96%
+10.39M
--
Jul 29, 2025
Tan (Cheng Guan)
10.20M
8.79%
+10.20M
--
Jul 29, 2025
Ching (Choon Hwa)
9.80M
8.45%
+9.80M
--
Jul 29, 2025
Invesco Capital Management LLC
89.66K
0.08%
+89.66K
--
Sep 30, 2025
UBS Financial Services, Inc.
62.60K
0.05%
+57.33K
+1087.84%
Jun 30, 2025
Virtu Americas LLC
13.97K
0.01%
+13.97K
--
Jun 30, 2025
Forsakringsaktiebolaget Skadinviska Enskilda
5.63K
0%
+1.79K
+46.68%
Aug 07, 2024
Zhou (Feng)
532.00
0%
-8.61K
-94.18%
Jul 23, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Invesco Golden Dragon China ETF
0.1%
Invesco Golden Dragon China ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Date
Type
Ratio
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
May 18, 2022
Merger
20→1
May 18, 2022
Merger
20→1
View more
